China’s strategic shift toward global biopharmaceutical innovation

Chinese pharmaceutical and biotech companies are increasingly seeking to expand beyond domestic borders, with particular interest in entering European (EU/EEA) markets – an ambition further accelerated by U.S. tariff policies. Over the past two decades, China has rapidly evolved into a global leader in biopharmaceutical innovation, propelled by significant investments in research, strong advancements in […]

Understanding the new EMA variation requirements

The recently updated EMA variation requirements reflect a major revision of both the legal framework and its practical guidance. It is essential to understand the distinct roles of the legally binding Variation Regulation and the accompanying EMA Variation Guideline, as well as the key drivers behind their revision and the practical implications for regulatory submissions.

Promotional compliance – major updates in 2025 for the Nordic region

With 2025 coming to a close, we have seen several important updates to Nordic promotional compliance codes over the past year. This overview highlights the key developments affecting promotional activities in the Nordics and outlines their implications for pharmaceutical and healthcare stakeholders.

The new FASS improves user experience

Fass (FASS) has, since 1966, been the central source of quality-assured pharmaceutical information in Sweden. 25 years ago, Fass went online for the first time. On November 8, the new Fass was launched, marking the most significant update and modernisation since its inception.

Linnea Brodin

Finance Manager

BSc Business and Economics

Linnea is our Finance Manager. She has a BSc in Business and Economics from Södertörns University and has previously worked in the accounts payable department at Huddinge Kommun.

Staffan Thunell

Founding partner

BSc Economics and BA

Staffan has a long background in entrepreneurship within the life science industry. He has 20+ years experience from posit­ions as Founder, Chair­man, CEO and CFO within medical affairs consulting and small pharma. Previously Staffan worked in executive positions in big pharma and specialty pharma companies.